EPIBRAIN · The importance of the epigenome in tumour development and recurrence
7РП — „Хора“ (Действия „Мария Кюри“)
- Период
- 2014-05-01 → 2018-04-30
- Финансиране от ЕС
- 100 000 €
- Участници
- 1
- Схема
- MC-CIG
Линиите свързват координатора с партньорите.
Накратко на български
Епигеномът на туморите в мозъка се анализира чрез профили на ДНК метилирането, за да се създадат диагностични инструменти като класификатора MethPed. Това помага за по-точна диагноза, проследяване на лечението и подобряване на качеството на живот на пациентите.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
The importance of the epigenome in tumour development and recurrence
The aim of the project was to explore the epigenome of brain tumours. Both to provide tools for improving the diagnosis, outcome predictions and monitoring treatment responses of cancer patients and to decipher the role of epigenetic aberrations in tumours and how to target them for improving survival and quality of life of patients. The project has revealed issues that can limit the use of so called differentiation therapy for aggressive brain tumours which should be taken into account when designing new warranted therapy for glioblastoma using the concepts of differentiation therapy. The project has also used DNA methylation profiles from paediatric brain tumours to develop a diagnostic classifier, called MethPed. The classifier is currently being evaluated in a national study in which all tumours from these patients are included with the aim of improving current diagnostics. The fellow, Helena Carén, has started her independent research group at the Sahlgrenska Cancer Center at the University of Gothenburg now composed of 12 team members including PhD students, postdocs, technicians and master students. She has established excellent collaboration with the University hospital in Gothenburg and key scientific collaborators at different Universities. Dr Carén has engaged in teaching and initiated and organised a new PhD course in cancer epigenetics to transfer knowledge to other researchers at the University. In 2016, she was appointed Associate Professor in molecular medicine.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
I aim to develop methods to reverse epigenetic anomalies in cancer stem cells (CSCs) to switch off the unlimited cell division and cancer growth and to understand the involvement of epigenetics in tumour development and recurrence. Epigenetic alterations are observed at the earliest stages of neoplasia within stem cells. Importantly, the alterations are reversible and can potentially be “treated”. In children, brain tumours are the leading cause of cancer-related mortality and morbidity. There are severe side-effects from treatment and survivors often experience substantial long-term problems. In vitro cultures of CSCs are indispensable tools for functional analyses and development of new therapies. However, up to now, paediatric CSC cultures have not been available. My unique cultures now enable us to study this disease closer. Induce differentiation of the CSCs will turn them less proliferative and less tumourigenic. Hence, I will screen for drugs that induce differentiation and determine the role epigenetics has on the stability of the specific differentiation stages. In addition, I will explore the relevance of the epigenome in tumour development by removing epigenetic marks through reprogramming the cells into induced pluripotent stem cells. These analyses will highlight target genes and pathways that are involved in the differentiation process. Furthermore, biomarkers will be implemented and I will study radiation-induced long-term effects to increase survival, quality of life and reduce adverse side-effects from treatment.
Оригинален текст от CORDIS (на английски).
Участници
- GOETEBORGS UNIVERSITET · GoeteborgКоординаторШвеция
Връзки
Данни: CORDIS, © Европейски съюз